* agilon health inc AGL.N AGL is expected to show a rise
in
quarterly revenue when it reports results on May 9.
* The Austin Texas-based company is expected to report a
64.9% increase in revenue to $1.078 billion from $653.45 million
a year ago, according to the mean estimate from 14 analysts,
based on Refinitiv data. The company's guidance on March 1 2023,
for the period ended March 31, was for revenue between $1.07
billion and $1.09 billion.
* Refinitiv's mean analyst estimate for agilon health inc
is for
earnings of 2 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for agilon
health inc
is $29, above its last closing price of $24.51.
The company's guidance on March 1 2023 for the period ended
March 31 was for Earnings before Interest, Taxes, Depreciation
and Amortization of between USD1.07 billion and USD37 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.07 -0.09 -0.14 Missed -62.8
Sep. 30 2022 -0.06 -0.05 -0.07 Missed -40
Jun. 30 2022 -0.02 -0.02 -0.05 Missed -177.8
Mar. 31 2022 0.00 0.00 0.00 Met -100
Dec. -0.14 -0.11 -0.14 Missed -27.3
31 2021
Sep. 30 2021 -0.10 -0.10 -0.09 Beat 6.9
Jun. 30 2021 -0.06 -0.05 -0.79 Missed -1,336
.4
Mar. 31 2021 -0.03 -0.03 -0.05 Missed -66.7
This summary was machine generated May 6 at 00:46 GMT. All
figures in US dollars unless otherwise stated